These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 37789862)
21. Lysine-Based Small Molecule Sensitizes Rifampicin and Tetracycline against Multidrug-Resistant Konai MM; Haldar J ACS Infect Dis; 2020 Jan; 6(1):91-99. PubMed ID: 31646866 [TBL] [Abstract][Full Text] [Related]
22. Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Danis-Wlodarczyk KM; Wozniak DJ; Abedon ST Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943709 [TBL] [Abstract][Full Text] [Related]
23. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Fischetti VA Viruses; 2018 Jun; 10(6):. PubMed ID: 29875339 [TBL] [Abstract][Full Text] [Related]
24. Loss of β-Ketoacyl Acyl Carrier Protein Synthase III Activity Restores Multidrug-Resistant Escherichia coli Sensitivity to Previously Ineffective Antibiotics. Hong Y; Qin J; Verderosa AD; Hawas S; Zhang B; Blaskovich MAT; Cronan JE; Totsika M mSphere; 2022 Jun; 7(3):e0011722. PubMed ID: 35574679 [TBL] [Abstract][Full Text] [Related]
25. Synergy between Active Efflux and Outer Membrane Diffusion Defines Rules of Antibiotic Permeation into Gram-Negative Bacteria. Krishnamoorthy G; Leus IV; Weeks JW; Wolloscheck D; Rybenkov VV; Zgurskaya HI mBio; 2017 Oct; 8(5):. PubMed ID: 29089426 [TBL] [Abstract][Full Text] [Related]
26. Bacteriophages that infect Gram-negative bacteria as source of signal-arrest-release motif lysins. Gontijo MTP; Vidigal PMP; Lopez MES; Brocchi M Res Microbiol; 2021 Mar; 172(2):103794. PubMed ID: 33347948 [TBL] [Abstract][Full Text] [Related]
27. Intrinsic Antimicrobial Peptide Facilitates a New Broad-Spectrum Lysin LysP53 to Kill Li C; Jiang M; Khan FM; Zhao X; Wang G; Zhou W; Li J; Yu J; Li Y; Wei H; Yang H ACS Infect Dis; 2021 Dec; 7(12):3336-3344. PubMed ID: 34788533 [TBL] [Abstract][Full Text] [Related]
28. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. Al Salman J; Al Dabal L; Bassetti M; Alfouzan WA; Al Maslamani M; Alraddadi B; Elhoufi A; Enani M; Khamis FA; Mokkadas E; Romany I; Somily A; Kanj S Int J Antimicrob Agents; 2020 Oct; 56(4):106104. PubMed ID: 32721603 [TBL] [Abstract][Full Text] [Related]
29. The alarming antimicrobial resistance in ESKAPEE pathogens: Can essential oils come to the rescue? Yu Z; Tang J; Khare T; Kumar V Fitoterapia; 2020 Jan; 140():104433. PubMed ID: 31760066 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus. Ma Q; Guo Z; Gao C; Zhu R; Wang S; Yu L; Qin W; Xia X; Gu J; Yan G; Lei L Antonie Van Leeuwenhoek; 2017 Mar; 110(3):347-355. PubMed ID: 27943012 [TBL] [Abstract][Full Text] [Related]
31. Membrane-Permeable Antibacterial Enzyme against Multidrug-Resistant Chen X; Liu M; Zhang P; Leung SSY; Xia J ACS Infect Dis; 2021 Aug; 7(8):2192-2204. PubMed ID: 34232613 [TBL] [Abstract][Full Text] [Related]
33. Phages and their lysins: Toolkits in the battle against foodborne pathogens in the postantibiotic era. Huang Z; Zhang Z; Tong J; Malakar PK; Chen L; Liu H; Pan Y; Zhao Y Compr Rev Food Sci Food Saf; 2021 Jul; 20(4):3319-3343. PubMed ID: 33938116 [TBL] [Abstract][Full Text] [Related]
34. Improvement of the Antibacterial Activity of Phage Lysin-Derived Peptide P87 through Maximization of Physicochemical Properties and Assessment of Its Therapeutic Potential. Vázquez R; Doménech-Sánchez A; Ruiz S; Sempere J; Yuste J; Albertí S; García P Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290106 [TBL] [Abstract][Full Text] [Related]
35. PaP1, a Broad-Spectrum Lysin-Derived Cationic Peptide to Treat Polymicrobial Skin Infections. Heselpoth RD; Euler CW; Fischetti VA Front Microbiol; 2022; 13():817228. PubMed ID: 35369520 [TBL] [Abstract][Full Text] [Related]
36. Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance. Schuch R; Cassino C; Vila-Farres X Front Microbiol; 2022; 13():841905. PubMed ID: 35308352 [TBL] [Abstract][Full Text] [Related]
37. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. Matsuzaki S; Rashel M; Uchiyama J; Sakurai S; Ujihara T; Kuroda M; Ikeuchi M; Tani T; Fujieda M; Wakiguchi H; Imai S J Infect Chemother; 2005 Oct; 11(5):211-9. PubMed ID: 16258815 [TBL] [Abstract][Full Text] [Related]
38. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients]. Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922 [No Abstract] [Full Text] [Related]
39. Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii. Thandar M; Lood R; Winer BY; Deutsch DR; Euler CW; Fischetti VA Antimicrob Agents Chemother; 2016 May; 60(5):2671-9. PubMed ID: 26856847 [TBL] [Abstract][Full Text] [Related]
40. Antimicrobial Agents That Inhibit the Outer Membrane Assembly Machines of Gram-Negative Bacteria. Choi U; Lee CR J Microbiol Biotechnol; 2019 Jan; 29(1):1-10. PubMed ID: 29996592 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]